NCT06166836 2026-03-25
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Active not recruiting
InxMed (Shanghai) Co., Ltd.
BeOne Medicines
Servier
Eisai Inc.
Gilead Sciences
Byondis B.V.
NEC Bio B.V
Fujian Haixi Pharmaceuticals Co., Ltd.
Gilead Sciences
Abbisko Therapeutics Co, Ltd
Klus Pharma Inc.
Pyxis Oncology, Inc
InventisBio Co., Ltd
Canwell Biotech Limited
Idera Pharmaceuticals, Inc.